These use E3 ubiquitin ligases to promote the degradation of proteins, rather than inhibiting their function like most traditional small molecules. While a focused class of marketed cancer drugs ...

Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...

We have selected the protein group of RING type ubiquitin E3 ligases to assign them in plant developmental stages and organs by gene expression profiles, by high throughput phenotyping of ...

These innovative compounds leverage the ubiquitin-proteasome system (UPS) to degrade challenging targets, providing new avenues for intervention beyond traditional small molecules. However, the power ...

Professor Zoran Rankovic’s group is developing PROTACs, Molecular Glue Degraders, and E3 ubiquitin ligase chemical probes to study cancer biology and develop novel cancer drugs. Our group's research ...